2022 NATIONAL CONFERENCE

Friday & Saturday
September 9-10
Welcome to the 2022 ABTA National Conference

Welcome to the American Brain Tumor Association’s 29th Annual National Conference — the largest brain tumor educational conference specifically designed for patients, caregivers and survivors, across all ages and tumor types.

Our goal: to provide you with access to the nation’s leading medical and research experts and to empower you with the information you need to navigate the physical and emotional journey of a brain tumor diagnosis.

New to the program this year, you can engage and connect with other attendees via roundtable and speed networking sessions. Our hope is that these sessions will foster new and deeper connections within our community. We truly have a dynamic program in store for you, to not only empower you with the best-in-class information, but to also inspire you through the personal stories of patients and caregivers.

We’re proud to welcome Matt Tifft as our Keynote Speaker for this year’s conference. A six-year Brain Tumor Survivor and Advocate, Matt is also the youngest team owner in NASCAR history and a former driver. Matt continues to push for brain tumor awareness and research through both his NASCAR team Live Fast Motorsports and his advocacy work. Matt will share “Changing Lanes: From NASCAR Driver to Brain Tumor Survivor.” Thank you, Matt, for being part of the ABTA family.

I also want to recognize the dedication and leadership of our conference Co-Chairs, Nancy Ann Oberheim Bush, MD, PhD, Assistant Professor, Neurological Surgery and Neurology, Clinical Director of Neuro-Oncology, University of California San Francisco; and Vinai Gondi, MD, Director of Research & Education, Northwestern Medicine Proton Center; and Co-Director, Brain Tumor Center, Northwestern Medicine Cancer Center Warrenville. As nationally recognized experts, they have curated a program that will provide you with the latest treatment advancements and care strategies, supporting all stages of a brain tumor diagnosis.

We really look forward to spending time with you. You continue to inspire us and move us forward in our mission. Thanks for being here and enjoy the conference!

Ralph A. DeVitto
President & CEO
American Brain Tumor Association

PS: Visit abta.org to learn more about the resources available to you and the many ways you can be part of the ABTA mission.
Dear Conference Attendees,

Welcome to the American Brain Tumor Association 2022 National Conference, the largest educational meeting for brain tumor patients, survivors, and caregivers.

We’re excited to bring you a dynamic, two-day lineup of informative sessions featuring cutting-edge research and innovative treatments in the management of brain tumors. You will hear from some of the most highly respected, patient-focused leaders in brain tumor research and care.

The ABTA National Conference program is designed for patients and caregivers to remain abreast of the rapidly changing field of neuro-oncology, which drives how we diagnose, monitor and manage brain tumors, as well as the development of new treatments.

We’re also excited to introduce an interactive conference platform, which we hope will elevate the sense of community between attendees and speakers. We know the importance of patients and caregivers learning not just from the experts, but also from each other. Speed networking and tumor-specific breakout sessions will allow you to choose sessions that are the most meaningful to you.

We hope the 2022 ABTA National Conference will be an invaluable and enriching experience. Thank you so much for participating. We look forward to spending time with you.

Sincerely,

Vinai Gondi
MD, Director of Research & Education, Northwestern Medicine Proton Center; and Co-Director, Brain Tumor Center, Northwestern Medicine Cancer Center Warrenville

Nancy Ann Oberheim Bush
MD, PhD, Assistant Professor, Neurological Surgery and Neurology; Clinical Director of Neuro-Oncology, University of California San Francisco

“We hope to create an atmosphere where patients and caregivers can interact with each other and the speakers and feel a real sense of community.”

- 2022 ABTA National Conference Co-Chairs
Matt Tifft, 26-year-old NASCAR Team Owner of Live Fast Motorsports, is the youngest owner in the NASCAR Cup Series. He is a former NASCAR Cup Series driver who is used to living in the fast lane. However, Matt’s professional driving career was sidelined after being diagnosed with a brain tumor in 2016. He quickly underwent surgery and eventually made his way back to the track with renewed purpose.

Matt resides outside of Charlotte, N.C., where he works in the racing industry as the youngest team owner in NASCAR history. He partners with charitable organizations like the ABTA to help lead the push for new treatments and breakthrough research to ultimately find cures for brain tumors.

In 2021, Matt drove the ABTA No. 78 Racecar to honor brain tumor survivors, folks who have passed away and family members affected by brain tumors. He was recently named a Forbes “30 Under 30” awardee for the Class of 2022.

“There are so many of us who have a similar story to share — my goal is to push for a change in a positive light for the entire brain tumor community.”
JOEL A. GINGRAS JR. AWARD RECIPIENT

Mark Gilbert, MD, Chief, Senior Investigator, Neuro-Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health; CCR Director

At the National Cancer Institute (NCI), Dr. Mark Gilbert leads a robust team of researchers and clinicians performing cutting-edge research in the field of neuro-oncology. In his pursuit of advancing brain tumor treatments, Dr. Gilbert also aspires to make clinical and translational research more accessible, so that physicians around the world can make a collective impact on neuro-oncology.

Throughout his career, Dr. Gilbert has gained international recognition for his roles in different clinical trial initiatives. In 2005, he was appointed Director of the Brain Tumor Trials Collaborative (BTTC), which seeks to expand clinical trial access to patients across the country. In 2006, Dr. Gilbert launched the Collaborative Ependymoma Research Network (CERN), where he served as (former) Director and Principal Investigator studying this rare form of CNS cancer.

Since 2011, Dr. Gilbert has been actively involved with the ABTA, presenting several webinars, speaking at Patient & Family Meetings, and participating in several mock tumor boards at the ABTA National Conference.

In 2020, he served as a National Conference co-chair, where he crafted a dynamic, patient-centric program at the height of the COVID-19 pandemic. Dr. Gilbert has also collaborated with the ABTA on the NCI-CONNECT partnership, a comprehensive oncology network that evaluates rare CNS tumors to help improve approaches to treatment and care.

“For his commitment to the ABTA mission, including his focus on education, research collaboration and expansion of clinical trial access, the ABTA is proud to recognize Dr. Gilbert for his leadership.”

- Nicole Willmarth, PhD
  ABTA Chief Mission Officer

About the Joel A. Gingras Award

Since 2010, the American Brain Tumor Association has awarded the Joel A. Gingras Jr. Award, our highest honor, to recognize an individual, organization or group that has made significant contributions to the Association’s mission through philanthropy, advocacy, discovery or patient care.
Deborah Rizzo, ABTA Volunteer

Deborah Rizzo truly lives every day to the fullest and makes a significant impact towards fulfilling the ABTA mission. Since the passing of her beloved college friend, Billy Misik, who lost his battle with GBM at the age of 21, and that of a close family friend, Lou Zucker, Deborah has devoted her time and effort to increasing brain tumor awareness and raising funds for brain tumor research.

What started as a bucket-list item, in honor of a friend, turned into 10 years of racing, fundraising, educating, and advocating for the ABTA. In 2012, Deborah established “Team Carpe Diem” to inspire others to live by Billy’s motto, “Seize the Day,” his mantra while battling GBM. Deborah and Team Carpe Diem have since been running marathons — including the Bank of America Chicago Marathon (twice) — half marathons, 10ks and 5ks in several states. Their sole purpose: to raise funds for brain tumor research through the ABTA.

While participating in these events, Deborah has written the names of Billy, Lou and others who’ve passed from brain tumors on her running shoes, so that they run with her and are not forgotten. Deborah’s efforts to date have raised nearly $20,000 for brain tumor research.

Like Juliana Schafer, Deborah demonstrates creativity, dedication, perseverance, and heartfelt empathy to those who have lost loved ones to brain tumors. As a music therapist, Deborah helps others, including brain tumor patients, process their emotions through the power of music. She presented “Music Therapy with Caregivers for Pediatric Brain Cancer and Brain Tumor Patients” in Philadelphia in 2018 at Brainfest, an event dedicated to raising funds and awareness for the advancement in the understanding and treatment of brain tumors.

As with Juliana Schafer, there is no quit in Deborah Rizzo. Her tremendous passion and unwavering support of the ABTA through her volunteerism continues to benefit the brain tumor community. Thank you, Deborah, for your service.

About the Juliana Schafer Spirit of Hope Award

The Juliana Schafer Spirit of Hope Award recognizes and honors individuals, organizations or groups who generously donate their time and talents to further the ABTA mission. The award is named after Juliana Schafer, a long-time volunteer for the ABTA. Juliana was passionate about the ABTA’s mission, from the patient and caregiver resources to the funding of cutting-edge research it provides. Juliana, her family and friends were dedicated to fundraising for and increasing awareness of the ABTA. Even from her hospice bed, Juliana was on her phone, raising money through her Breakthrough for Brain Tumors 5k (BT5K) team, aptly named, Team Hope. The pride she took in those efforts brought her comfort to the very end. Juliana passed in 2021, but her spirit continues to live on.
**Program Schedule**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 10:00 AM – 10:30 AM CT  | **WELCOME**  
Emily Lippert, ABTA Program Manager  
Ralph DeVitto, ABTA President & CEO  
Carla Varner, ABTA Board Chair  
Vinai Gondi, MD, Northwestern Medicine Proton Center, Northwestern Medicine Cancer Center, Warrenville; ABTA National Conference Chair  
Nancy Ann Oberheim Bush, MD, PhD, University of California San Francisco; ABTA National Conference Chair |
| 10:30 AM – 10:45 AM CT  | **HOW THE ABTA IS COMMITTED TO YOU**  
Learn more about ABTA's mission, which includes funding brain tumor research and providing invaluable resources and programs to patients, caregivers and families.  
Nicole Willmarth, PhD, ABTA Chief Mission Officer |
| 10:45 AM – 11:15 AM CT  | **ABTA ROUNDTABLES**  
Join this interactive session to learn more about the ABTA and the services we offer. Hear from staff who oversee volunteering, research funding, patient support, as well as from volunteers. You will get the chance to ask your important questions directly to ABTA staff and volunteers.  
**SPEED NETWORKING**  
Already know about the ABTA? Use this time to get to know others at the conference by engaging in speed networking with other patients, caregivers, researchers, healthcare professionals, and more! |
| 11:15 AM – 11:45 AM CT  | **PUSHING THE BOUNDARIES OF SURGERY: AWAKE BRAIN MAPPING TECHNIQUES**  
Review of advances in awake brain mapping techniques.  
**Learning Objectives:**  
• Receive an overview of what awake mapping is and how it is performed.  
• Understand the eligibility requirements for awake mapping techniques.  
• Learn about the importance of tumor location in brain mapping.  
• Explore neurosurgical advances aimed at improving patient outcomes.  
Shawn Hervey-Jumper, MD, FAANS, University of California San Francisco  
**Patient Voice:** Liz Salmi |
| 11:45 AM – 12:20 PM CT  | **BREAK** |
| 11:50 AM – 12:20 PM CT  | **UNDERSTANDING YOUR TUMOR: WHAT, HOW, WHY, AND W.H.O.?**  
Provides a simple understanding of brain tumor classification and why it is important.  
**Learning Objectives:**  
• Identify how brain tumors form.  
• Understand the importance of tumor classification and the role of the pathologist.  
• Receive an overview of the 2021 World Health Organization (WHO) update to tumor classification and understand how this affects you or your loved one.  
David Louis, MD, Massachusetts General Hospital, Harvard Medical School |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 – 12:55 PM CT</td>
<td>LUNCH SESSION FEATURING: ABTA SPONSORS</td>
<td>Listen in as our sponsors provide information about their products and services, including brain tumor clinical trials and treatments. For more information, visit the sponsor booths and other brain tumor advocacy organizations for resources using your Whova app. Also during the lunch session, ABTA-funded researcher presentations are available for viewing. Most presentations are on-demand, but some researchers will be available to answer questions live.</td>
</tr>
<tr>
<td>12:55 – 1:35 PM CT</td>
<td>KEYNOTE SESSION</td>
<td>Changing Lanes: From NASCAR Driver to Brain Tumor Survivor</td>
</tr>
<tr>
<td></td>
<td><strong>Matt Tifft</strong>, a 26-year-old NASCAR team owner, former driver, and brain tumor survivor shares his journey navigating his diagnosis at the height of his career. He will share how resilience helped him continue to chase his dreams to become a leader both on the track and in his advocacy efforts for the brain tumor community.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Matt Tifft, Brain Tumor Survivor &amp; Advocate, NASCAR Team Owner</em></td>
<td></td>
</tr>
<tr>
<td>1:35 – 1:40 PM CT</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>1:40 – 2:05 PM CT</td>
<td>TRANSCENDING THE LIMITS OF CHEMOTHERAPY: NOVEL STRATEGIES TO TREAT MENINGIOMAS</td>
<td>Review of current and future systemic therapies and devices to treat meningiomas.</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Recognize current and promising future systemic chemotherapies for meningiomas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Understand how the immune system is being harnessed in the treatment and management of meningiomas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Learn about targeted therapies for meningiomas and how personalized medicine can impact you or your loved one.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Nancy Ann Oberheim Bush, MD, PhD, University of California San Francisco; ABTA National Conference Chair</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Patient Voice:</strong> Diane Zhang</td>
<td></td>
</tr>
<tr>
<td>2:05 – 2:10 PM CT</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Recognize current and promising future systemic chemotherapies for gliomas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Learn about techniques in overcoming the blood-brain barrier and treatment resistance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Understand how the immune system is being harnessed in the treatment and management of gliomas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Learn about targeted therapies for gliomas and how personalized medicine can impact you or your loved one.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Erin Dunbar, MD, Piedmont Brain Tumor Center</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Patient Voice:</strong> Neill P. Ferrill</td>
<td></td>
</tr>
</tbody>
</table>
## Program Schedule

### Friday, September 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:55 – 3:00 PM CT</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>3:00 – 3:35 PM CT</td>
<td>FROM BENCH TO BEDSIDE TO BEAM: RADIOThERAPY ADVANCES FOR BRAIN TUMORS</td>
<td>Understanding how radiotherapy serves as the backbone of treatment for most brain tumors and how innovative technologies and techniques have improved its safety.</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify various radiotherapy technologies.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn how radiotherapy functions in treating brain tumors and how side effects can be minimized.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the implications of radiotherapy on improved survivorship and quality of life of brain tumor patients.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patient Voice: Daniel Ponton</td>
<td></td>
</tr>
<tr>
<td>3:35 – 3:40 PM CT</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>3:40 – 4:05 PM CT</td>
<td>A WINDOW INTO THE BRAIN: NEURO-IMAGING 101</td>
<td>Review of imaging techniques most commonly used to monitor brain tumors.</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review imaging techniques most commonly used in the diagnosis and ongoing management of brain tumors.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the challenges and advantages of these imaging techniques.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn how to review and understand your imaging reports with you doctor.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soonmee Cha, MD, University of California San Francisco</td>
<td></td>
</tr>
<tr>
<td>4:05 – 4:15 PM CT</td>
<td>CLOSING REMARKS</td>
<td>Introduction by Carla Varner, ABTA Board Chair</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Susan Kramer, ABTA Co-Founder, Honorary Board Member</td>
</tr>
</tbody>
</table>
# Program Schedule

**Saturday, September 10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 10:00 – 10:15 AM  | WELCOME                                    | Ralph DeVitto, ABTA President & CEO  
| CENTRAL TIME (CT) |                                            | Don and Gail Segal, ABTA Honorary Board Members                                                                                       |
| 10:15 – 10:45 AM  | JOEL A. GINGRAS JR. AWARD PRESENTATION     | Since 2011, the ABTA has awarded the Joel A. Gingras Jr. Award to recognize an individual, organization or group that has made a significant contribution to the ABTA's mission through philanthropy, advocacy, research or patient care.  
|                  |                                            | Introductions by Carla Varner, ABTA Board Chair  
|                  |                                            | Johnathan Gingras, President, Joel A. Gingras, Jr. Memorial Foundation                                                                 |
|                  | **Recipient:** Mark R. Gilbert, MD, Chief, Senior Investigator, Neuro-Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health; CCR Director |
| 10:45 – 11:00 AM  | JULIANA SCHAFER SPIRIT OF HOPE AWARD        | The Juliana Schafer Spirit of Hope Award is designed to recognize and honor those individuals, groups or organizations who have generously donated their time and talents to further the mission of the ABTA through their volunteer efforts.  
|                  |                                            | Introductions by Kelly Sitkin, ABTA Chief Development Officer  
|                  |                                            | Chad Schafer, Juliana’s Husband                                                                                                       |
|                  | **Recipient:** Deborah Rizzo, founding member of Team Carpe Diem |                                                                                                                                                           |
| 11:00 – 11:05 AM  | BREAK                                      |                                                                                                                                         |
| 11:05 AM – 12:20 PM | BEHIND THE SCENES OF A BRAIN TUMOR BOARD   | Listen in as a multi-disciplinary panel of expert clinicians simulate the review of brain tumor cases to determine the best course of treatment for patients.  
|                  |                                            | **Learning Objectives:**  
|                  |                                            | • Learn how experts work together to care for individual patients.  
|                  |                                            | • Understand the role each expert plays in diagnosis and treatment planning.  
|                  |                                            | • Hear different perspectives on complicated cases.                                                                                     |
|                  |                                            | **Facilitator:** Mark R. Gilbert, MD, Chief, Senior Investigator, Neuro-Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health; CCR Director |
|                  |                                            | **Panelists:**  
|                  |                                            | Neuro-Oncologist: Nancy Ann Oberheim Bush, MD, PhD, University of California San Francisco; ABTA National Conference Chair |
|                  |                                            | Neurosurgeon: Mahua Dey, MD, University of Wisconsin  
|                  |                                            | Radiation Oncologist: Vinai Gondi, MD, Northwestern Medicine Proton Center, Northwestern Medicine Cancer Center, Warrenville; ABTA National Conference Chair |
|                  |                                            | Neuro-Pathologist: Craig Horbinski, MD, PhD, Northwestern University |
**Program Schedule**

**Saturday, September 10**

**12:20 – 12:55 PM CT**

**LUNCH SESSION FEATURING: ABTA SPONSORS**
Check out the Sponsor Booths and Brain Tumor Nonprofit and Advocacy Organizations for resources. Additionally, visit the ABTA-funded Researcher Presentations. Presentations are on-demand, but some researchers will be available to answer questions live.

**Meet the ABTA Board of Directors**
Meet the ABTA Board of Directors and hear why they are involved with the ABTA.

*Carla Varner, Chair*
*Ram Subramanian, Vice Chair, Chair of Mission Committee*
*Bob Kruchten, Treasurer, Chair of Finance and Audit Committee*
*Brandon Starkoff, Secretary*
*Jim Reilly, Immediate Past Chair*
*Mitch Berger, MD, Member*
*Danny Monson, Member*
*Mindee Plugues, Member, Chair of Development Committee*
*Patti Tsai-Steiner, Member*

**12:55 – 1:40 PM CT**

**BREAKOUT SESSION: HOT TOPICS FOR BRAIN TUMORS**
Select and join one of these interactive breakout sessions where you will engage with a brain tumor specialist to learn about treatment options and cutting-edge research.

**Brain Tumors and Proton Therapy: Preserving Neuro-cognition and Optimizing Survivorship**
Receive an overview of the role of proton therapy in brain tumor treatment and explore ongoing research in this area.

*Vinai Gondi, MD, Northwestern Medicine*

**Meningiomas/Skull Base Tumors: Local Therapy Discussion**
Learn about the biology, epidemiology, presentation and treatment of meningiomas and skull base tumors.

*David R. Raleigh, MD, PhD, University of California San Francisco*

**Adolescent and Young Adult Brain Tumors**
Explore treatment options and survivorship issues for adolescent and young adult brain tumor patients. Tumor types covered will include Medulloblastoma, Ependymoma and Germ Cell Tumors.

*Anita Mahajan, MD, Mayo Clinic*

**Metastatic Brain Tumors**
Learn about the different treatment modalities used to manage metastatic brain tumors.

*Seema Nagpal, MD, Stanford University*

**Low Grade Gliomas:**

**Oligodendrogliomas and Astrocytomas: Treat Now Versus Treat Later**
*Discuss the importance of treatment timing and understand what goes into deciding between surveillance and starting active treatment.*

*Vinay Puduvalli, MD, MD Anderson Cancer Center*
### Program Schedule

**Saturday, September 10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:55 – 1:40 PM CT</strong></td>
<td><strong>BREAKOUT SESSION: HOT TOPICS FOR BRAIN TUMORS (CONTINUED)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Low Grade Gliomas</strong></td>
</tr>
<tr>
<td></td>
<td><strong>IDH Mutated Oligodendrogliomas and Astrocytomas: IDH Inhibitors</strong></td>
</tr>
</tbody>
</table>
|               | Learn about IDH inhibitors, what they are, and how they impact brain tumor treatment.  
|               | *Ingo K. Mellinghoff, MD, FACP, Memorial Sloan Kettering Cancer Center*   |
|               | **Glioblastoma/Grade 4 Astrocytoma**                                    |
|               | **Viral Therapy/Immunotherapy**                                          |
|               | Discuss current and ongoing trials and research on the use of oncolytic viruses and immunotherapy in the treatment of glioblastoma.  
|               | *Rimas Lukas, MD, Northwestern Medicine*                                |
|               | **Personalized Medicine/Targeted Therapy**                              |
|               | Explore the impact of biomarkers and genetics on treatment decisions and advancements.  
|               | *Howard Colman, MD, PhD, University of Utah Health*                     |
|               | **Improve Blood-Brain Penetration**                                     |
|               | Understand the role of the blood-brain barrier and techniques used to enhance treatment delivery.  
|               | *Adam Sonabend Wothalter, MD, Northwestern Medicine*                    |
| **1:40 – 1:45 PM CT** | **BREAK**                                                                 |
| **1:45 – 2:45 PM CT** | **LIVING YOUR BEST LIFE...AS A PATIENT AND CAREGIVER**                   |
|               | Understanding approaches to optimizing quality of life as a brain tumor patient or caregiver.  
|               | **Learning Objectives:**                                                 |
|               | • Recognize the importance of palliative care and quality of life management for patients and survivors.  
|               | • Discuss common issues in ensuring quality of life for patients, survivors, and caregivers.  
|               | • Understand how patients can integrate approaches such as palliative care, pain management and self-care into their brain tumor management during and after treatment.  
|               | • Learn how caregivers can manage stress, engage in self-care and integrate evidence-based practices to avoid burnout.  
|               | *Nimish Mohile, MD, University of Rochester Medical Center*              |
|               | *Jamie Jacobs, PhD, Massachusetts General Hospital, Harvard Medical School* |
| **2:45 – 3:00 PM CT** | **CLOSING REMARKS & ADJOURNMENT**                                        |
|               | *Ralph DeVitto, ABTA President & CEO*                                    |
|               | *Carla Varner, ABTA Board Chair*                                         |
|               | *Vinai Gondi, MD, Northwestern Medicine Proton Center, Northwestern Medicine Cancer Center, Warrenville; ABTA National Conference Chair* |
|               | *Nancy Ann Oberheim Bush, MD, PhD, University of California San Francisco; ABTA National Conference Chair* |
Maximizing Your Conference Experience

### PREPARE FOR THE CONFERENCE

1. Plan ahead and choose the sessions you want to join in advance. **Note:** the conference takes place in **Central Time.**
2. Find a comfortable and quiet space to focus.
3. Plan to enter the conference 15 minutes before the first session to get familiar with navigating the Whova platform.
4. Have a notebook and pen handy to capture notes from each session.

### USING WHOVA

Whova is our conference virtual platform. You need to [download the Whova app](#) on your phone or web browser (Google Chrome recommended) to attend the conference. Create an account with Whova using the same email as when you registered. You can find detailed instructions on setting up your Whova account in this [tutorial video](#) or via this [guide](#).

### ENGAGE YOUR WAY

Connecting during the conference is easy with Whova. Start by going to your **Profile** to add your headshot and bio. Whova will automatically match you with attendees who share similar interests (see the **Recommended** tab). You can even send other attendees a chat or video call invite through their profile. Other options include...

**Community:** Join discussion forums and create or join virtual meetups with fellow attendees.

**Speed Networking:** Meet and get to know other conference attendees.

**Roundtables:** Meet with ABTA staff and volunteers to learn more about our services and share your ideas on how the ABTA can serve you better!

**Research Posters:** To access research posters presented by ABTA’s Alumni Research Network, click on the “Agenda” tab in Whova and select “Researchers.” Vote for your favorite research poster and you will be entered into a prize drawing.

**Exhibit Hall:** Visit our virtual Exhibit Hall to explore our sponsor and brain tumor resources booths. Some booth reps will be available to chat with you live.

**Contests:** Get rewarded for your participation! Enter to win prizes by collecting passport “stamps” while engaging in exhibitor booths, posting pictures on the photo wall and completing challenges.

### ATTENDING SESSIONS

To attend a live session, find it in the **Agenda** tab and click **View Session.** You will be directed to a livestream where you will need to click **Join Audio** to hear the presenter(s). You can choose to view the presentation in full screen. Throughout the session, you can type questions in the Session Q&A tab, chat with other attendees in topic-based discussions, and answer live polls.

### PRESENTATION AUDIO/VIDEO

You’ll be able to hear and see presentations and speakers during the conference. However, your own audio and video will be muted throughout the conference. The only time you will have access to audio and video will be during Breakout Sessions, Speed Networking and Roundtables. Make sure to allow Whova access to your camera and microphone on your computer or mobile device.

### TROUBLESHOOTING

If using a computer, connect your device to a hard-wired Internet connection (not wi-fi) running at high speed. Ensure all applications and programs with notifications or reminders are closed. If you’re using your phone and the Whova mobile app, ensure you have wifi enabled instead of cellular data. **Please note:** the ABTA cannot provide technical assistance regarding your internet access.
Thank you to our generous sponsors...

CORPORATE PARTNERS

DIAMOND SPONSORS

GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

FUNDED IN PART BY

Genentech
A Member of the Roche Group
WALK WITH PURPOSE

Together, let’s raise critical funds for brain tumor research and support services.

REGISTER
patientforward

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

visit novocure.com
FDA-cleared GammaTile Surgically Targeted Radiation Therapy (STaRT) is an immediate, internal treatment that provides a proven head STaRT against tumor regrowth.

Find a treatment center near you at gammatile.com.

For full product and safety information, refer to the Instructions for Use.

SEE MORE AT GLEOLAN.COM
World-Class Care for Brain Tumors

At Northwestern Medicine, we combine innovative and compassionate care with a relentless search for cures, all to improve the lives of patients with cancer. Anchored by Northwestern Memorial Hospital, ranked No. 10 in the U.S. for Neurology and Neurosurgery, and No. 9 in the U.S. for Cancer care by U.S. News & World Report, 2021–2022, we offer access to the latest treatments and technology, including many pioneering brain tumor clinical trials downtown and in the suburbs. Each treatment plan is designed by a team of experts in medical oncology, radiation oncology, neuro-oncology, neurology, neurological surgery, neuropathology and neuroradiology, tailored to your needs and specific to the tumor to be treated.

Learn more at nm.org/braintumor.
The Ivy Brain Tumor Center is located at Barrow Neurological Institute, an international leader in neurological care. As one of the most extensive brain tumor trial programs, patients come to us from around the world to access promising new therapies that fit their exact circumstances. No stone should be left unturned for brain tumor patients facing the fight of their lives.

Request a free clinical trial screening today.
EVERY PATIENT DESERVES A VOICE

At Immunomic Therapeutics, Inc. (ITI), we are pioneering the study of nucleic acid immunotherapy platforms with a goal of improving cancer treatments.

Immunomic Therapeutics main focus is investigating dendritic cell vaccination for Glioblastoma (GBM), a rare and devastating brain cancer that affects more than 13,000 people annually. Learn more about our ATTAC-II Clinical Trial (Phase II) for newly diagnosed Glioblastoma Multiforme (www.clinicaltrials.gov) or go to www.immunomix.com.

We are also applying our nucleic acid vaccine platform for next generation GBM therapies and developing it to address other cancers, including those driven by viruses.

At ITI, we are dedicated to supporting patients. With our efforts in GBM, we offer travel assistance for patients enrolling in the ATTAC-II trial (NCT02465268). The coverage includes all travel expenses for each patient and a caregiver for the duration of the treatment (including airfare, rental car, and hotel accommodations).

TOGETHER, OUR VOICE BECOMES STRONGER
www.immunomix.com

VBI VACCINES
Activating the Power Within

It takes the power of many great minds and organizations to solve the toughest challenges.

We are a proud sponsor of the American Brain Tumor Association!

VBI is committed to the fight against Glioblastoma

To find out more about our immunotherapeutic candidate targeting GBM, which has now received both FDA Fast Track Designation and Orphan Drug Designation, visit our website at:

www.vbivaccines.com
Another Mayo Clinic innovation in brain tumor treatment: Helping you feel less alone.

Visit our website for more information about brain tumor care at Mayo Clinic.

ONCOSYNERGY IS A PROUD SPONSOR OF THE ABTA NATIONAL CONFERENCE

Be a pioneer for glioblastoma research

Individuals with recurrent glioblastoma may be eligible for participation in our Clinical Trial

Connect with us to learn more!

Instagram @OncoSynergy
Facebook @OncoSynergy
Twitter @OncoSynergy
info@oncosynergy.com
www.oncosynergy.com
Highly Developed Body of Evidence in High Grade Glioma

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay

Kiyatec Predict™ provides oncologists with patient tumor-specific treatment response insights to guide treatment planning

2 North Main St. • Greenville, SC 29601
864.502.2013
www.kiyatec.com

Developing sonodynamic therapy, a new noninvasive targeted therapy for aggressive brain cancers

Currently recruiting patients in our clinical trial in diffuse intrinsic pontine glioma (NCT05123534) and will soon be recruiting in recurrent glioblastoma (NCT05370508)

Visit sonalasense.com or clinicaltrials.gov
What’s your favorite social media channel?

Follow the ABTA:
THANK YOU